

DEPARTMENT OF HEALTH AND HUMAN SERVICES



Stacie Weeks, JD MPH Administrator

DIVISION OF HEALTH CARE FINANCING AND POLICY Helping people. It's who we are and what we do.

Drug Utilization Review

Board Meeting Minutes

Date of Meeting: Thursday, July 27, 2023

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP),

Drug Use Review Board

Agenda Item	Record		Notes
1. Call to Order and Roll Call	It was announced the meeting is being recorde	DHCFP Staff Present were as follows:	
	Chairperson Wheeler called the meeting to order at 1:04 p.m. on July 27, 2023. Chairperson Wheeler took the roll.		 Clemons, Roshanda, MD, Medical Director Griffin, Karen, Senior Deputy Attorney General (SDAG) Olsen, David, Chief of Pharmacy Services
		Present Absent	Gudino, Antonio, Manager of
		_	Pharmacy Services
	 Jennifer Wheeler, Pharm.D., Chair 		Flowers, Ellen, Program Officer I,
	 Netochi Adeolokun, Pharm.D., Vice Chair 		Pharmacy Unit
	Crystal Castaneda, MD		
	Jessica Cate, Pharm.D.		Magellan Rx Staff Present were as
	Dave England, Pharm.D.		follows:
	Brain Le, DO		Mishra, Raj, Pharm.D., Clinical Account
	Rebecca Sparks, PA-C		Manager
	Jim Tran, Pharm.D.		 Kim, James, Pharm.D., Dir. Clinical Account Services
			 Martinez, Chris, Sr. Business Analyst

		Mai repriet • • • • • • The Atta Not rever a sign is not	Killpack, Andy, Pharm.D., Dir. Specialty Clinical Solutions Imaged Care Organization Presentatives present were as follows: Lim, Luke, Pharm.D., Anthem Bitton, Ryan, Pharm.D., Health Plan of Nevada Beranek, Thomas, Pharm.D., Silver Summit Health Plan Tran, Jimmy, Pharm.D., Molina Healthcare Public attendee list is included as eachment A. Ite: Participants may not have chosen to real their identity, and in the absence of ign-in sheet, the attendee list's accuracy not assured.
2. General Public Comment Telephonic and web comment was called for, and the phone lines were opened.	2. General Public Commen		
No public comment was provided.		No public comment was provided.	
3. Administrative	3. Administrative		
a. For Possible Action: Review Vice Chair Adeolokun moved to approve the minutes as presented,			
and Approve Meeting and Board Member England seconded the motion. Minutes from April 20, 2023			
Minutes from April 20, 2023. A vote was taken, and the results were as follows from members in	iviinutes from April 2		
attendance (in favor, against, and abstentions where applicable):		·	
Yes No Abst. ■ Jennifer Wheeler, Pharm.D., Chair □ □			
Netochi Adeolokun, Pharm.D., Vice Chair			

	 Crystal Castaneda, MD Jessica Cate, Pharm.D.
	Dave England, Pharm.D. Davis La BO
	Brain Le, DO
	Rebecca Sparks, PA-C
	• Jim Tran, Pharm.D.
b. Status Update by DHCFP	Chief of Pharmacy Services David Olsen provided five announcements. On August 28th, we are holding a public hearing for a State Plan Amendment regarding the pricing and reimbursement for Physician Administered Drugs. Providers should begin contacting Magellan to obtain prior authorization for specific drugs for the Fee-for-Service recipients for Physician Administered Drugs. Providers will be able to complete the prior authorization process through either web or phone. Also, in addition to the prior authorization program, there is now a fee schedule for Physician Administered Drugs. Please check the rates page on the DFCHP website for more information. Due to the close of the 82nd legislative session, the Pharmacy Services Unit is working to implement a number of bills which will involve making updates to pharmacy policy. We are working on that now and those changes will be going forward over then the next seven to eight months. We do have some organizational changes to announce, Dr Rashonda Clemens, who we have previously announced as the Nevada Medicaid Medical director will now be overseeing the Pharmacy Units as well as are Durable Medical Equipment Unit and will be combining into one unit. Also, as a result of the 82nd Legislative Session, the Nevada Medicaid approved budget included the position of a Pharmacy Director. The position is posted at our HR website which is H
	r.nv.gov and if there is interest or you know someone that is

	 interested, CVs and resumes are welcome to be sent to our RX info@dhcfp.nv.gov inbox. Our last announcement is that we would like to thank Antonio Brown, who has served as a state employee for approximately the past 10 years. Most of that with Nevada Medicaid. He is moving to a new position, itis still in pharmacy, but is no longer with the state. His last day will be August 4th and he is greatly appreciated and will be extremely missed. 	
4. Clinical Presentations		
 a. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Strensiq. 		
 i. <u>Public comment</u> on proposed clinical prior authorization criteria. 	Telephonic and web comment was called for, and the phone lines were opened.	
ii. Presentation of	No public comment was provided. Dr. Raj Mishra provided the clinical background and indications for	
utilization and clinical information.	Strensiq. Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization of Strensiq.	
	 Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 	

iii. Discussion by Board and review of utilization data. iv. Proposed adoption of updated prior authorization criteria.	Chairperson Wheeler asked for comments from No comments were made. Board Member Le moved to approve the crite Magellan, and Board Member England second A vote was taken, and the results were as follows attendance (in favor, against, and abstentions)					
	 Jennifer Wheeler, Pharm.D., Chair Netochi Adeolokun, Pharm.D., Vice Chair Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D. 	Yes	No	Abst.		
 For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Myfembree. 						
 i. <u>Public comment</u> on proposed clinical prior authorization criteria. 	Telephonic and web comment was called for, and the phone lines were opened. Public comment was provided by Doctor Cassandra Lickert, Director of Medical Management Markets and Rowe with Sumitomo Pharma America, formerly known as Mylan Sciences.					

ii.	Presentation of utilization and clinical	Dr. Mishra provided the clinical background an Myfembree.	nd indi	cations	s for	
	information.					
		Dr. Mishra reviewed the proposed criteria pre and discussed the utilization for Myfembree.	sented	I in the	binder	
						I
		 Dr. Lim with Anthem, approved of the pro utilization presented. 				
		Dr. Bitton with Health Plan of Nevada, app.	roved	of the	proposed	I
		criteria and utilization presented.				I
		Dr. Miro with Silver Summit Health Plan, a		ed of th	ne	I
		 proposed criteria and utilization presented Dr. Tran with Molina Healthcare, approved 		o prop	ocod	I
		criteria and utilization presented.	ווו וט ג	e propi	oseu	I
iii.	Discussion by Board and review of utilization	Chairperson Wheeler asked for comments fro	m the	Board	Members.	
	data.	No comments were made.				
iv.	Proposed adoption of	Chair Wheeler moved to approve the criteria a	•		•	I
	updated prior authorization criteria.	Magellan, and Vice Chair Adeolokun seconded				
		A vote was taken, and the results were as follows from members in				I
		attendance (in favor, against, and abstentions	wher	e appli	cable):	
			Yes	No	Abst.	
		Jennifer Wheeler, Pharm.D., Chair	\boxtimes			I
		Netochi Adeolokun, Pharm.D., Vice Chair	\boxtimes			I
		Crystal Castaneda, MD	\boxtimes			I
		 Jessica Cate, Pharm.D. 	\boxtimes			I
		Dave England, Pharm.D.	\boxtimes			I
		Brain Le, DO	\boxtimes			I
		Rebecca Sparks, PA-C				I
		Jim Tran, Pharm.D.			\boxtimes	I
						ı

	For Descible Astinin		
C.	For Possible Action:		
	Discussion and possible		
	adoption of prior		
	authorization criteria and/or		
	quantity limits for Tzield .		
	i. Public comment on	Telephonic and web comment was called for, and the phone lines	
	proposed clinical prior	were opened.	
	authorization criteria.		
		No public comment was provided.	
	ii. Presentation of	Dr. Mishra provided the clinical background and indications for	
	utilization and clinical	Tzield.	
	information.		
		Dr. Mishra reviewed the proposed criteria presented in the binder	
		and discussed the utilization for Tzield.	
		Dr. Lim with Anthem, approved of the proposed criteria and	
		utilization presented.	
		·	
		Dr. Bitton with Health Plan of Nevada, approved of the proposed	
		criteria and utilization presented.	
		Dr. Miro with Silver Summit Health Plan, approved of the	
		proposed criteria and utilization presented.	
		Dr. Tran with Molina Healthcare, approved of the proposed	
		criteria and utilization presented.	
ii	i. Discussion by Board and	Chairperson Wheeler asked for comments from the Board Members.	
	review of utilization data.		
		No comments were made.	
iv	v. Proposed adoption of	Vice Chair Adeolokun moved to approve the criteria as presented by	
	updated prior	Magellan, and Board Member Castaneda seconded the motion.	
	authorization criteria.		
		A vote was taken, and the results were as follows from members in	
		attendance (in favor, against, and abstentions where applicable):	
		attendance (in ravor, against, and abstentions where applicable).	
L			

	Yes No Abst. Igennifer Wheeler, Pharm.D., Chair Netochi Adeolokun, Pharm.D., Vice Chair Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D.	
d. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for infliximab biosimilars.		
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. Public comment was provided by Amy Hale pharmacist with Janssen scientific affairs.	
ii. Presentation of utilization and clinical information.	 Dr. Mishra discussed the indications for infliximab biosimilars. Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization of infliximab biosimilars. Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. Dr. Miro with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved of the proposed 	

	criteria and utilization presented.				
iii. Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No comments were made.				
iv. Proposed adoption of updated prior authorization criteria.	Board Member Castaneda moved to approve to presented by Magellan, and Board Member Le A vote was taken, and the results were as follo attendance (in favor, against, and abstentions				
	 Jennifer Wheeler, Pharm.D., Chair Netochi Adeolokun, Pharm.D., Vice Chair Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D. 		No	Abst.	
e. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Opdivo.					
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. Public comment was provided by Alexandra Sharer, Pharmacist with Field Health Economics and Outcomes Research Scientist at Bristol Myers Squibb.				

ii.	Presentation of utilization and clinical	Dr. Andy Killpack discussed the indications for	Opdiv	0.		
	information.	Dr. Killpack reviewed the proposed criteria presented in the binder				
	illiorillation.	and discussed the utilization of Opdivo.				
		Dr. Lim with Anthem, approved of the proposed criteria and				
		utilization presented.				
		Dr. Bitton with Health Plan of Nevada, approved of the proposed				
		criteria and utilization presented.				
		 Dr. Miro with Silver Summit Health Plan, a proposed criteria and utilization presented 		ed of th	ne	
		Dr. Tran with Molina Healthcare, approved		e nron	nsed	
		criteria and utilization presented.	2 01 011	Сргор	oscu	
iii.	Discussion by Board and	Chairperson Wheeler asked for comments fro	m the	Board	Members.	
	review of utilization					
	data.	No comments were made.				
iv.	Proposed adoption of	Vice Chair Adeolokun moved to approve the cr		•	•	
	updated prior authorization criteria.	Magellan, and Board Member Castaneda seconded the motion.				
	authorization criteria.	A vote was taken, and the results were as follows from members in			mbers in	
		attendance (in favor, against, and abstentions				
			Yes	No	Abst.	
		Jennifer Wheeler, Pharm.D., Chair	\boxtimes			
		Netochi Adeolokun, Pharm.D., Vice Chair	\boxtimes			
		Crystal Castaneda, MD Crystal Castaneda, MD	\boxtimes			
		Jessica Cate, Pharm.D. Page Fraland Pharm D. Page Fraland Pharm D. Page Fraland Pharm D. Page Fraland Pharm D.				
		Dave England, Pharm.D.Brain Le, DO	\boxtimes			
		Rebecca Sparks, PA-C			\boxtimes	
		Jim Tran, Pharm.D.			\boxtimes	
		- Jan Han, Hammer				
		1				

Di ac au qu	or Possible Action: scussion and possible loption of prior athorization criteria and/or antity limits for metrexed.	
i.	Public comment on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened.
ii.	Presentation of utilization and clinical information.	No public comment was provided. Dr. Killpack discussed the indications for Pemetrexed. Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization for Pemetrexed. Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. Dr. Miro with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.
iii.	Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No comments were made.
iv.	Proposed adoption of updated prior authorization criteria.	Board Member Le moved to approve the criteria as presented by Magellan, and Board Member Castaneda seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):
		Yes No Abst. ◆ Jennifer Wheeler, Pharm.D., Chair □ □

	 Netochi Adeolokun, Pharm.D., Vice Chair Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C 				
	Jim Tran, Pharm.D.				
g. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Perjeta.					
 i. <u>Public comment</u> on proposed clinical prior authorization criteria. 	Telephonic and web comment was called for, a were opened. No Public comment was provided.	nd the	phone	lines	
ii. Presentation of utilization and clinical information.	 Dr. Killpack discussed the indications for Perjeta Dr. Killpack reviewed the proposed criteria presand discussed the utilization of Perjeta. Dr. Lim with Anthem, approved of the proputilization presented. Dr. Bitton with Health Plan of Nevada, approriteria and utilization presented. Dr. Miro with Silver Summit Health Plan, approposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved criteria and utilization presented. 	ented posed of roved opproved	criteria of the p	and proposed	

 iii. Discussion by Board and review of utilization data. iv. Proposed adoption of updated prior authorization criteria. 	Chairperson Wheeler asked for comments from the Board Members. No comments were made. Board Member Castaneda moved to approve the criteria as presented by Magellan, and Vice Chair Adeolokun seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):		
	Yes • Jennifer Wheeler, Pharm.D., Chair • Netochi Adeolokun, Pharm.D., Vice Chair • Crystal Castaneda, MD • Jessica Cate, Pharm.D. • Dave England, Pharm.D. • Brain Le, DO • Rebecca Sparks, PA-C • Jim Tran, Pharm.D.	No Abst.	
h. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for ranibizumab.			
 i. Public comment on proposed clinical prior authorization criteria. 	Telephonic and web comment was called for, and the were opened. No Public comment was provided.	e phone lines	

ii. Presentation		r. Killpack discussed the indications for ra	nibizuma	b.	
utilization an		r Killmank ravioused the proposed exitoria	nroconto	din +h	a bindar
information.		 r. Killpack reviewed the proposed criteriand discussed the utilization of ranibizuma 	•	a in th	e binder
	ar	nd discussed the utilization of ranibizuma	D.		
	•	Dr. Lim with Anthem, approved of the utilization presented.	proposed	criteri	a and
	•	Dr. Bitton with Health Plan of Nevada,	approved	of the	proposed
		criteria and utilization presented.			
	•	Dr. Beranek with Silver Summit Health	Plan, app	roved	of the
		proposed criteria and utilization presen	nted.		
	•	Dr. Tran with Molina Healthcare, appro	oved of th	e prop	osed
		criteria and utilization presented.			
iii. Discussion by review of util		hairperson Wheeler asked for comments	from the	Board	Members.
data.	N	o comments were made.			
iv. Proposed add	•	soard Member England moved to approve			
updated prio authorizatior		y Magellan, and Vice Chair Adeolokun se	conded th	ne moti	on.
		vote was taken, and the results were as f ttendance (in favor, against, and abstenti			
			Vos	N.a	A la a t
		Jennifer Wheeler, Pharm.D., Chair	Yes ⊠	No □	Abst. □
	•	•		_	
	•	Netochi Adeolokun, Pharm.D., Vice Chi			
	•	Crystal Castaneda, MD			
	•	Jessica Cate, Pharm.D.	\boxtimes		
	•	Dave England, Pharm.D.	\boxtimes		
	•	Brain Le, DO			
	•	Rebecca Sparks, PA-C			\boxtimes
	•	Jim Tran, Pharm.D.	Ш		\boxtimes
i. For Possible					
Discussion ar	nd possible				

	adoption of prior authorization criteria and/or quantity limits for rituximab IV .		
i.	Public comment on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. No Public comment was provided.	
ii.	Presentation of utilization and clinical information.	 Dr. Killpack discussed the indications for rituximab IV. Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of rituximab IV. Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved of the proposed 	
iii.	Discussion by Board and review of utilization data.	criteria and utilization presented. Chairperson Wheeler asked for comments from the Board Members. No comments were made.	
iv.	Proposed adoption of updated prior authorization criteria.	Vice Chair Adeolokun moved to approve the criteria as presented by Magellan, and Board Member Castaneda seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable): Yes No Abst. Jennifer Wheeler, Pharm.D., Chair	

	-	_		
 Netochi Adeolokun, Pharm.D., Vice Chair Crvstal Castaneda. MD 	\boxtimes			
•		П	П	
·				
Jim Tran, Pharm.D.			\boxtimes	
Telephonic and web comment was called for, a were opened. No Public comment was provided.	nd the	e phone	e lines	
 Dr. Killpack reviewed the proposed criteria pre and discussed the utilization of rituximab SQ. Dr. Lim with Anthem, approved of the proputilization presented. Dr. Bitton with Health Plan of Nevada, approviteria and utilization presented. Dr. Beranek with Silver Summit Health Plan proposed criteria and utilization presented. 	oosed roved n, appr	d in the criteria of the proved o	and proposed f the	
_	 Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D. Telephonic and web comment was called for, a were opened. No Public comment was provided. Dr. Killpack discussed the indications for rituxing and discussed the utilization of rituximab SQ. Dr. Lim with Anthem, approved of the proposed criteria presented. Dr. Bitton with Health Plan of Nevada, appropriate and utilization presented. Dr. Beranek with Silver Summit Health Plan proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved. 	 Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D. Telephonic and web comment was called for, and the were opened. No Public comment was provided. Dr. Killpack discussed the indications for rituximab SQ. Dr. Killpack reviewed the proposed criteria presented and discussed the utilization of rituximab SQ. Dr. Lim with Anthem, approved of the proposed utilization presented. Dr. Bitton with Health Plan of Nevada, approved criteria and utilization presented. Dr. Beranek with Silver Summit Health Plan, approposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved of the 	 Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D. Telephonic and web comment was called for, and the phonomer were opened. No Public comment was provided. Dr. Killpack discussed the indications for rituximab SQ. Dr. Killpack reviewed the proposed criteria presented in the and discussed the utilization of rituximab SQ. Dr. Lim with Anthem, approved of the proposed criteria utilization presented. Dr. Bitton with Health Plan of Nevada, approved of the criteria and utilization presented. Dr. Beranek with Silver Summit Health Plan, approved of proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved of the proposed 	 Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D. Dr. Killpack discussed the indications for rituximab SQ. Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. Dr. Beranek with Molina Healthcare, approved of the proposed Dr. Tran with Molina Healthcare, approved of the proposed Dr. Tran with Molina Healthcare, approved of the proposed

iv	review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No comments were made. Board Member England moved to approve the criteria as presented by Magellan, and Board Member Le seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):				
		 Jennifer Wheeler, Pharm.D., Chair Netochi Adeolokun, Pharm.D., Vice Chair Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D. 	Yes X X	No	Abst.	
k.	For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for SCIG (immune globulin SQ).					
i.	Public comment on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, were opened. No Public comment was provided.	and th	e phon	e lines	
ii.	Presentation of utilization and clinical information.	Dr. Killpack discussed the indications for SCIG Dr. Killpack reviewed the proposed criteria pre and discussed the utilization of SCIG (immune	sente	d in the	e binder	

		 Dr. Lim with Anthem, approved of the proutilization presented. Dr. Bitton with Health Plan of Nevada, approved and utilization presented. Dr. Beranek with Silver Summit Health Plaproposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved criteria and utilization presented. 	oroved n, appo d. d of the	of the roved o	proposed of the osed
iii.	Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from No comments were made.	m the	Board	Members.
iv.	Proposed adoption of updated prior authorization criteria.	Vice Chair Adeolokun moved to approve the criteria as presented by Magellan, and Board Member Castaneda seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):			
		 Jennifer Wheeler, Pharm.D., Chair Netochi Adeolokun, Pharm.D., Vice Chair Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D. 	Yes	No	Abst.
l.	For Possible Action: Discussion and possible adoption of prior authorization criteria and/or				

	rantity limits for Soliris culizumab).					
i.	Public comment on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, a were opened. No Public comment was provided.	and th	e phon	e lines	
ii.	Presentation of utilization and clinical information.	 Dr. Killpack discussed the indications for Soliris Dr. Killpack reviewed the proposed criteria pre and discussed the utilization of Soliris (eculizur) Dr. Lim with Anthem, approved of the proputilization presented. Dr. Bitton with Health Plan of Nevada, app criteria and utilization presented. Dr. Beranek with Silver Summit Health Plan proposed criteria and utilization presented. 	 utilization presented. Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved of the proposed 			
iii.	Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from No comments were made.	m the	Board	Members.	
iv.	Proposed adoption of updated prior authorization criteria.	Board Member Le moved to approve the criteria as presented by Magellan, and Board Member Castaneda seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):			tion.	
		 Jennifer Wheeler, Pharm.D., Chair Netochi Adeolokun, Pharm.D., Vice Chair Crystal Castaneda, MD Jessica Cate, Pharm.D. 	Yes ⊠ ⊠	No	Abst.	

	 Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D. 	
m. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Susvimo.		
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. No Public comment was provided.	
ii. Presentation of utilization and clinical information.	 Dr. Killpack discussed the indications for Susvimo. Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of Susvimo. Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 	
iii. Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No comments were made.	

iv. Proposed adoption of updated prior authorization criteria.	Board Member England moved to approve the criteria as presented by Magellan, and Vice Chair Adeolokun seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):
	Yes No Abst. Jennifer Wheeler, Pharm.D., Chair □ □ Netochi Adeolokun, Pharm.D., Vice Chair □ □ Crystal Castaneda, MD □ □ □ Jessica Cate, Pharm.D. □ □ Dave England, Pharm.D. □ □ □ Brain Le, DO □ □ □ Rebecca Sparks, PA-C □ □ □ □ Jim Tran, Pharm.D. □ □ □
n. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Tecentriq.	
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. No Public comment was provided.
ii. Presentation of utilization and clinical information.	Dr. Killpack discussed the indications for Tecentriq. Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of Tecentriq. Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.

		Dr. Bitton with Health Plan of Nevada, approved of the proposed			
		criteria and utilization presented.			-
		 Dr. Beranek with Silver Summit Health Pla 		roved o	of the
		proposed criteria and utilization presente			
		Dr. Tran with Molina Healthcare, approve	d of th	e prop	osed
iii.	Discussion by Doord and	criteria and utilization presented. Chairperson Wheeler asked for comments fro		Doord	Mambara
111.	review of utilization	·	ını tne	Board	Members.
iv.	data. Proposed adoption of	No comments were made. Board Member Le moved to approve the crite	rio oc	nrocont	tod by
IV.	updated prior authorization criteria.	Magellan, and Board Member Castaneda seco		•	•
		A vote was taken, and the results were as follo			
		attendance (in favor, against, and abstentions	wher	e appli	cable):
			Vaa	NI a	A la at
		Jennifer Wheeler, Pharm.D., Chair	Yes ⊠	No	Abst. □
		Netochi Adeolokun, Pharm.D., Vice Chair	\boxtimes		
		Crystal Castaneda, MD	\boxtimes		
		 Jessica Cate, Pharm.D. 	\boxtimes		
		Dave England, Pharm.D.	\boxtimes		
		Brain Le, DO	\boxtimes		
		Rebecca Sparks, PA-C			\boxtimes
		Jim Tran, Pharm.D.			\boxtimes
	For Possible Action:				
	Discussion and possible				
	adoption of prior authorization criteria and/or				
	quantity limits for				
	trastuzumab IV.				
,	dastazamas i v.				

i.	<u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. No Public comment was provided.				
ii.	Presentation of utilization and clinical information.	Dr. Killpack discussed the indications for trastu Dr. Killpack reviewed the proposed criteria pre and discussed the utilization of trastuzumab IV	sente		e binder	
		 Dr. Lim with Anthem, approved of the proutilization presented. Dr. Bitton with Health Plan of Nevada, approvided and utilization presented. Dr. Beranek with Silver Summit Health Plaproposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved. 	roved n, app	of the	proposed of the	
iii.	Discussion by Board and review of utilization data.	•	Chairperson Wheeler asked for comments from the Board Members.			
iv.	Proposed adoption of updated prior authorization criteria.	Board Member England moved to approve the by Magellan, and Chair Wheeler seconded the A vote was taken, and the results were as follows:	oard Member England moved to approve the criteria as presented y Magellan, and Chair Wheeler seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):			
			Yes	No	Abst.	
		Jennifer Wheeler, Pharm.D., Chair	\boxtimes			
		Netochi Adeolokun, Pharm.D., Vice Chair	\boxtimes			
		Crystal Castaneda, MD	\boxtimes			
		Jessica Cate, Pharm.D.	\boxtimes			
		Dave England, Pharm.D.	\boxtimes			
		Brain Le, DO	\boxtimes			

p. For Possible Ac Discussion and adoption of pri- authorization of quantity limits trastuzumab Sc	ossible r teria and/or or
i. <u>Public com</u> proposed c authorizati	nical prior were opened.
ii. Presentatio utilization a information	of Dr. Killpack discussed the indications for trastuzumab SQ. and clinical
iii. Discussion review of u data.	y Board and Chairperson Wheeler asked for comments from the Board Members. No comments were made.

iv. Proposed adoption of updated prior authorization criteria.	Board Member England moved to approve the criteria as presented by Magellan, and Vice Chair Adeolokun seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):	
	Yes No Abst. Igennifer Wheeler, Pharm.D., Chair Netochi Adeolokun, Pharm.D., Vice Chair Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D.	
q. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Ultomiris.		
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. Public comment was provided by Alexandra Sharer pharmacist with BMS (Bristol Myers Squibb).	
ii. Presentation of utilization and clinical information.	Dr. Killpack discussed the indications for Ultomiris. Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of Ultomiris.	

		 Dr. Lim with Anthem, approved of the proputilization presented. Dr. Bitton with Health Plan of Nevada, apportieria and utilization presented. Dr. Beranek with Silver Summit Health Plan proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved criteria and utilization presented. 	roved n, app l. d of th	of the roved o	proposed of the osed
iii.	Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from No comments were made.	m the	Board	Members.
iv.	Proposed adoption of updated prior authorization criteria.	Board Member Castaneda moved to approve to presented by Magellan, and Vice Chair Adeolo motion. A vote was taken, and the results were as follo attendance (in favor, against, and abstentions)	kun se ws fro	econde om mer	d the mbers in
		Jennifer Wheeler, Pharm.D., Chair	Yes ⊠	No	Abst.
		Netochi Adeolokun, Pharm.D., Vice Chair	\boxtimes		
		Crystal Castaneda, MD	\boxtimes		
		Jessica Cate, Pharm.D.	\boxtimes		
		Dave England, Pharm.D.	\boxtimes		
		Brain Le, DO	\boxtimes		
		Rebecca Sparks, PA-C			\boxtimes
		Jim Tran, Pharm.D.			
Dis	or Possible Action: scussion and possible loption of prior				

	ithorization criteria and/or uantity limits for Yervoy .		
I.	Public comment on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. No Public comment was provided.	
II.	Presentation of utilization and clinical information.	 Dr. Killpack discussed the indications for Yervoy. Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of Yervoy. Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 	
III.	Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No comments were made.	
IV.	Proposed adoption of updated prior authorization criteria.	Board Member Castaneda moved to approve the criteria as presented by Magellan, and Vice Chair Adeolokun seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):	

		.,	• • • • • • • • • • • • • • • • • • • •	• • • • • • • • • • • • • • • • • • • •	
	 Jennifer Wheeler, Pharm.D., Chair 	Yes ⊠	No	Abst. □	
	Netochi Adeolokun, Pharm.D., Vice Chair				
	Crystal Castaneda, MD	\boxtimes			
	 Jessica Cate, Pharm.D. 	\boxtimes			
	Dave England, Pharm.D.				
	Brain Le, DO	\boxtimes			
	Rebecca Sparks, PA-C			\boxtimes	
	 Jim Tran, Pharm.D. 				
	3 m man, mannie.				
s. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Zynlonta.					
I. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, were opened.	and th	e phon	e lines	
	No Public comment was provided.				
II. Presentation of utilization and clinical	Dr. Killpack discussed the indications for Zynlo	nta.			
information.	Dr. Killpack reviewed the proposed criteria pre	sente	d in the	binder	
	and discussed the utilization of Zynlonta.				
	Dr. Lim with Anthem, approved of the pro	posed	criteria	a and	
	utilization presented.				
	 Dr. Bitton with Health Plan of Nevada, app 	roved	of the	proposed	
	criteria and utilization presented.				
	Dr. Beranek with Silver Summit Health Pla		roved o	of the	
	proposed criteria and utilization presented	1.			

		Dr. Tran with Molina Healthcare, approve criteria and utilization presented.	d of th	e prop	osed		
III.	Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members.					
	udia.	No comments were made.					
IV.	Proposed adoption of updated prior authorization criteria.	Board Member Castaneda moved to approve the criteria as presented by Magellan, and Board Member England seconded the motion. A vote was taken, and the results were as follows from members in					
		attendance (in favor, against, and abstentions					
			Yes	No	Abst.		
		Jennifer Wheeler, Pharm.D., Chair	\boxtimes				
		Netochi Adeolokun, Pharm.D., Vice Chair	\boxtimes				
		Crystal Castaneda, MD	\boxtimes				
		Jessica Cate, Pharm.D.	\boxtimes				
		Dave England, Pharm.D.	\boxtimes				
		Brain Le, DO	\boxtimes				
		Rebecca Sparks, PA-C			\boxtimes		
		Jim Tran, Pharm.D.			\boxtimes		
5. DUR	Board Requested Reports						
	Opioid Reports:	Dr. Mishra presented opioid utilization rep					
i. 	Opioid Trends	Dr. Lim presented opioid utilization reports.					
ii.	Count of Claims	Dr. Bitton presented opioid utilization reports.					
iii. iv.	Med Trend Top Members	Dr. Beranek presented opioid utilization reports.					
V.	Top Prescribers	Dr. Tran presented opioid utilization reports.					
v. vi.	Top Pharmacy	Chairperson Wheeler asked for comments from Board Members					
• • • • • • • • • • • • • • • • • • • •	. 5 6 1 1101111001	regarding Opioid Reports. The board discussed utilization and trends.					
		No additional action taken or motions for inves					

b. Standard DUR Reports: i. Top 10 Classes by Amount Paid ii. Top 10 Classes by Claim Count iii. Quarterly ProDUR Paid Claims Saving Report iv. Retro DUR Initiatives	 Dr. Mishra presented Standard DUR Reports Dr. Lim presented Standard DUR Reports. Dr. Bitton presented Standard DUR Reports Dr. Beranek presented Standard DUR Reports Dr. Tran presented Standard DUR Reports.
6. Closing Discussion	
a. Public Comment	Telephonic and web comment was called for, and the phone lines were opened. No public comment was provided.
b. For Possible Action: Date and location of the next meeting.	Chairperson Wheeler stated the next meeting is scheduled for October 19, 2023. Location: Hilton Garden Inn Reno
	Meeting adjourned at 3:04 pm

Attachment A – Members of the Public in Attendance

Sharer, Alexandra	Deb G (Guest)	D'Ambrosio, Beth
Santarone, Christopher	Hylla, Scott	McCutchan, Frank /US
Martinez, Shannan /US	Hale, Amy [JANUS]	Levin, Amy, MD
Cassandra Lickert	Michele Puyear (Guest)	Michael Zarob
Rushi Parikh	Jared Godwin	GNH (Gina Heinen)

Borysyuk, Maribel /US Matthew Wright Michal Mark Rosenberg Karen Ou (Guest) Sacro Sandee Merrick McNair, LaTanya Bobb Chris Johnson Jessica Cate (Guest) Roa, Ryan A Cheryl Donahue

Michael Pazirandeh Sacro, Janssen Bobby White

Attachment B – Submitted Written Comment

None